Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2007-002171-13 | EudraCT Number |
Not provided
Not provided
Decision not to pursue as single agent in the study population.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a Phase II, multicenter, single-arm, open-label study of oral lenalidomide monotherapy administered to subjects with relapsed or refractory T-cell lymphoma. This study will be conducted in two phases: a Treatment Phase and a Follow-up Phase.
Subjects who qualify for enrollment into the study will enter the Treatment Phase and receive single-agent lenalidomide 25 mg once daily on Days 1-21 every 28 days (28-day cycles). Subjects may continue participation in the Treatment Phase of the study for a maximum duration of 24 months, or until disease progression or unacceptable adverse events develop.
All subjects who discontinue the Treatment Phase for any reason will continue to be followed until progression of disease or until next lymphoma treatment is given, whichever comes first, during the Follow-up Phase.
Objectives:
Primary:
• To determine the efficacy of lenalidomide monotherapy in relapsed or refractory T-cell Non-Hodgkin's Lymphoma (NHL). Efficacy will be assessed by measuring the response rate, tumor control rate, duration of response, time to progression and progression free survival.
Secondary:
• To evaluate the safety of lenalidomide monotherapy as treatment for subjects with relapsed or refractory T-cell NHL.
Study was terminated. Study data assessment revealed that study drug is active, but is not likely to be sufficiently active as a single agent in this population for registration purposes.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lenalidomide | Experimental | Open-label, oral lenalidomide monotherapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lenalidomide | Drug | Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle |
|
| Measure | Description | Time Frame |
|---|---|---|
| Participants Categorized by Best Response as Determined by Investigator | Participant response assessed by investigator; criteria by B. Cheson in Journal of Clinical Oncology, 1999 (see article for more detail):
| Up to 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of Response | Kaplan-Meier Estimate of duration of response calculated as the time from first computed tomography (CT) Scan or magnetic resonance imaging (MRI) that demonstrates at least a partial response to the first documentation of disease progression, including death due to Non-Hodgkin's Lymphoma. | Up to 24 months |
Not provided
Inclusion Criteria:
Must understand and voluntarily sign an informed consent form.
Must be ≥ 18 years of age at the time of signing the informed consent form.
Must be able to adhere to the study visit schedule and other protocol requirements.
Biopsy-proven T-cell Non-Hodgkin's Lymphoma, either:
Relapsed or refractory to previous therapy for T-cell Non-Hodgkin's Lymphoma.
Must have received at least one prior combination chemotherapy regimen. There is no limit on the number of prior therapies.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kenichi Takeshita, MD | Celgene Corporation | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tower Cancer Research Foundation | Beverly Hills | California | 90211-1850 | United States | ||
| Cancer Center of Kansas |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23731832 | Result | Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013 Sep;49(13):2869-76. doi: 10.1016/j.ejca.2013.04.029. Epub 2013 May 31. |
Not provided
Not provided
Participants with relapsed or refractory, biopsy-proven, T-cell Non-Hodgkin's Lymphoma. Must have received at least one prior chemotherapy regimen which contained two cytotoxic agents.
Recruiting began March 2008; first participant enrolled 16 June 2008 and last participant enrolled 29 January 2010.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Single Agent Lenalidomide | Oral lenalidomide 25 mg daily for 21 days every 28 days as tolerated for up to 24 months, until disease progression, or an unacceptable adverse event occurs. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Time-to-Progression |
Kaplan-Meier estimate of time-to-progression is calculated as the time from the start of study drug therapy to the first documentation of progressive disease. |
| Up to 24 months |
| Progression-Free Survival | Kaplan-Meier estimate of progression-free survival is defined as the start of study drug therapy to the first observation of disease progression or death due to any cause. | Up to 24 months |
| Safety | Summary of Treatment-Emergent Events in Safety Population (participants with at least one dose of study drug). Events assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 3: Following is the scale: Grade 1=Mild Adverse Event (AE), Grade 2=Moderate AE, Grade 3=Severe and Undesirable AE, Grade 4=Life-threatening or Disabling AE, and Grade 5=Death Related to AE.) | Up to 24 months |
| Wichita |
| Kansas |
| 67214 |
| United States |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | United States |
| Western Pennsylvania Hospital | Pittsburgh | Pennsylvania | 15224 | United States |
| The Canberra Hospital Building 3, L 2 | Garran | Australian Capital Territory | 2605 | Australia |
| Cancer Therapy Centre | Liverpool | New South Wales | 2170 | Australia |
| Clinical Research Unit Cairns Base Hospital | Cairns | Queensland | 4870 | Australia |
| The Townsville Hospital | Douglas | Queensland | 4814 | Australia |
| Royal Brisbane & Women's Hospital | Herston | Queensland | 4029 | Australia |
| Ashford Cancer Centre | Ashford | South Australia | 5035 | Australia |
| Royal Adelaide Hospital L3 East Wing | North Terrace | South Australia | 5000 | Australia |
| Royal Hobart Hospital | Hobart | Tasmania | 7000 | Australia |
| Box Hill Hospital, 4th Floor, Clive Ward Centre | Box Hill | Victoria | 3128 | Australia |
| Monash Medical Centre | Clayton | Victoria | 3168 | Australia |
| Peter MacCallum Cancer Centre | East Melbourne | Victoria | 3002 | Australia |
| St Vincents Hospital | Fitzroy | Victoria | 3065 | Australia |
| Sir Charles Gairdner Hospital | Nedlands | Western Australia | 6009 | Australia |
| Institute Jules Bordet | Brussels | 1000 | Belgium |
| Cliniques Universitaires St Luc | Brussels | 1200 | Belgium |
| KUL | Leuven | 3000 | Belgium |
| Clinique St Pierre | Ottignies | 1340 | Belgium |
| Cliniques universitaires UCL de Mont-Godinne | Yvoir | 5530 | Belgium |
| CHU Hôtel Dieu | Nantes | Cedex 01 | 44093 | France |
| Hôpital Bretonneau | Tours | Cédex 1 | 37044 | France |
| CHU Hôpital Hôtel Dieu | Angers | Cédex 9 | 49033 | France |
| Hôpital Claude Huriez | Place de Verdun Cedex | Lille | 59037 | France |
| Hôpital Lapeyronie | Cedex | Montpellier | 34295 | France |
| Centre Hospitalier Lyon Sud | Lyon Sud | Pierre-Bénite | 69495 | France |
| CHRU Hôpitaux de Brabois - Hématologie | Vandœuvre-lès-Nancy | Rue Morvan Cedex | 54511 | France |
| Polyclinique Bordeaux Nord Aquitaine | Bordeaux | 33000 | France |
| Hôtel Dieu Pavillon Villemur Pasteur | Clermont-Ferrand | 63000 | France |
| Hopital Henri Mondor | Créteil | 94010 | France |
| CHU de Dijon | Dijon | 21000 | France |
| Hopital Michallon | Grenoble | 38043 | France |
| CHD Les Oudairies | La Roche-sur-Yon | 85000 | France |
| CHU Dupuytren | Limoges | 87042 | France |
| Hôpital N.D.de Bon Secours | Metz | 57000 | France |
| Hôpital Saint-Louis | Paris | 75010 | France |
| Hôpital Necker | Paris | 75015 | France |
| Hôpital de la Pitié Salpétriere | Paris | 75651 | France |
| CHU Rennes Hôpital Pontchaillou | Rennes | 35033 | France |
| Centre Henri Becquerel | Rouen | 76038 | France |
| Centre René Huguenin | Saint-Cloud | 92210 | France |
| Hôpital Purpan | Toulouse | 31059 | France |
| Centre Hospitalier | Valence | 26953 | France |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Single Agent Lenalidomide | Oral lenalidomide 25 mg daily for 21 days every 28 days as tolerated for up to 24 months, until disease progression, or an unacceptable adverse event occurs. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Age, Customized | Number | participants |
| |||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Race/Ethnicity, Customized | Number | participants |
| |||||||||||||||||||||||
| Region of Enrollment | Number | participants |
| |||||||||||||||||||||||
| Non-Hodgkin's Lymphoma Diagnosis/Histopathology | Non-Hodgkin's Lymphoma Diagnosis/Histopathology as assessed by local laboratory at study baseline. Cutaneous T-cell lymphoma,mycosis fungoides varient Extranodal Natural Killer (NK)T-cell lymphoma, nasal type Peripheral T-cell lymphoma, not otherwise characterized | Number | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Participants Categorized by Best Response as Determined by Investigator | Participant response assessed by investigator; criteria by B. Cheson in Journal of Clinical Oncology, 1999 (see article for more detail):
| Intent-to-treat (ITT) Population | Posted | Number | Participants | Up to 24 months |
|
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Duration of Response | Kaplan-Meier Estimate of duration of response calculated as the time from first computed tomography (CT) Scan or magnetic resonance imaging (MRI) that demonstrates at least a partial response to the first documentation of disease progression, including death due to Non-Hodgkin's Lymphoma. | Intent-to-treat (ITT) Population | Posted | Median | 95% Confidence Interval | Months | Up to 24 months |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Time-to-Progression | Kaplan-Meier estimate of time-to-progression is calculated as the time from the start of study drug therapy to the first documentation of progressive disease. | Due to early termination of study, data not analyzed. See outcome #4 for progression-free survival. | Posted | Up to 24 months |
|
| |||||||||||||||||||||||||||||||||||||||
| Secondary | Progression-Free Survival | Kaplan-Meier estimate of progression-free survival is defined as the start of study drug therapy to the first observation of disease progression or death due to any cause. | Intent-to-treat (ITT) Population | Posted | Median | 95% Confidence Interval | Months | Up to 24 months |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Safety | Summary of Treatment-Emergent Events in Safety Population (participants with at least one dose of study drug). Events assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 3: Following is the scale: Grade 1=Mild Adverse Event (AE), Grade 2=Moderate AE, Grade 3=Severe and Undesirable AE, Grade 4=Life-threatening or Disabling AE, and Grade 5=Death Related to AE.) | Safety Population (received at least one dose of study drug) | Posted | Number | Participants | Up to 24 months |
|
|
Up to 24 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Single Agent Lenalidomide | Oral lenalidomide 25 mg daily for 21 days every 28 days as tolerated for up to 24 months, until disease progression, or an unacceptable adverse event occurs. | 29 | 54 | 53 | 54 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Febrile neutropenia | Blood and lymphatic system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Haemolytic anaemia | Blood and lymphatic system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Leukopenia | Blood and lymphatic system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Lymph Node Pain | Blood and lymphatic system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Neutropenia | Blood and lymphatic system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Arrhythmia | Cardiac disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Tachycardia | Cardiac disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Aplasia | Congenital, familial and genetic disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Hypothyroidism | Endocrine disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Occular Vasculitis | Eye disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Odynophagia | Gastrointestinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Asthenia | General disorders | MedDRA 13.0 | Systematic Assessment |
| |
| General Physical Health Deterioration | General disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Hyperthermia | General disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Oedema Peripheral | General disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Bacterial Sepsis | Infections and infestations | MedDRA 13.0 | Systematic Assessment |
| |
| Cytomegalovirus Infection | Infections and infestations | MedDRA 13.0 | Systematic Assessment |
| |
| Infection | Infections and infestations | MedDRA 13.0 | Systematic Assessment |
| |
| Neutropenic Infection | Infections and infestations | MedDRA 13.0 | Systematic Assessment |
| |
| Neutropenic Sepsis | Infections and infestations | MedDRA 13.0 | Systematic Assessment |
| |
| Oral Candidiasis | Infections and infestations | MedDRA 13.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 13.0 | Systematic Assessment |
| |
| Pneumonia Pneumococcal | Infections and infestations | MedDRA 13.0 | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA 13.0 | Systematic Assessment |
| |
| Septic Shock | Infections and infestations | MedDRA 13.0 | Systematic Assessment |
| |
| Prothrombin Level Decreased | Investigations | MedDRA 13.0 | Systematic Assessment |
| |
| Decreased Appetite | Metabolism and nutrition disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Back Pain | Musculoskeletal and connective tissue disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Histiocytosis Haematophagic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 13.0 | Systematic Assessment |
| |
| Kaposi's Sarcoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 13.0 | Systematic Assessment |
| |
| Metastasis | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 13.0 | Systematic Assessment |
| |
| Peripheral T-cell Lymphoma Unspecified | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 13.0 | Systematic Assessment |
| |
| Tumour Flare | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 13.0 | Systematic Assessment |
| |
| Ataxia | Nervous system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Carotid Artery Stenosis | Nervous system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Cerebral Ischaemia | Nervous system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Somnolence | Nervous system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Transient Ischaemic Attack | Nervous system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Confusional State | Psychiatric disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Renal Failure | Renal and urinary disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Acute Pulmonary Oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Acute Respiratory Distress Syndrome | Respiratory, thoracic and mediastinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Bronchopneumopathy | Respiratory, thoracic and mediastinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Lung Infiltration | Respiratory, thoracic and mediastinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Drug Eruption | Skin and subcutaneous tissue disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Toxic Epidermal Necrolysis | Skin and subcutaneous tissue disorders | MedDRA 13.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Neutropenia | Blood and lymphatic system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Abdominal Pain | Gastrointestinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Dry Mouth | Gastrointestinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Dysphagia | Gastrointestinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Rectal Haemorrhage | Gastrointestinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Stomatitis | Gastrointestinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Asthenia | General disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Oedema Peripheral | General disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Pain | General disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Weight Decreased | Investigations | MedDRA 13.0 | Systematic Assessment |
| |
| Back Pain | Musculoskeletal and connective tissue disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Muscle Spasms | Musculoskeletal and connective tissue disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Tumour Flare | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 13.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Paraesthesia | Nervous system disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Renal Failure Acute | Renal and urinary disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Oropharyngeal Pain | Respiratory, thoracic and mediastinal disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Night Sweats | Skin and subcutaneous tissue disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | MedDRA 13.0 | Systematic Assessment |
| |
| Hypotension | Vascular disorders | MedDRA 13.0 | Systematic Assessment |
|
Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Associate Director, Clinical Trial Disclosure | Celgene | 1-888-260-1599 | clinicaltrialdisclosure@celgene.com |
| ID | Term |
|---|---|
| D016399 | Lymphoma, T-Cell |
| D008228 | Lymphoma, Non-Hodgkin |
| ID | Term |
|---|---|
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077269 | Lenalidomide |
| ID | Term |
|---|---|
| D010797 | Phthalimides |
| D010795 | Phthalic Acids |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D010881 | Piperidones |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D054833 | Isoindoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
| >65 years |
|
| Black |
|
| Hispanic |
|
| White |
|
| Other |
|
| Missing |
|
| Belgium |
|
| Australia |
|
|
| Angioimmunoblastic T-cell lymphoma |
|
| Cutaneous T-cell lymphoma, mycosis fungoides var. |
|
| Extranodal NK T-cell lymphoma, nasal type |
|
| Peripheral T-cell lymphoma, not otherwise charac |
|
| Title | Measurements |
|---|---|
|
| Stable Disease (SD) |
|
| Progressive Disease (PD) |
|
| No Response Assessment |
|
| Other |
|
| Tumor Control (CR+CRu+PR+SD) |
|
|
|
|